Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 31:10:1161.
doi: 10.3389/fneur.2019.01161. eCollection 2019.

Nimodipine-Induced Blood Pressure Changes Can Predict Delayed Cerebral Ischemia

Affiliations

Nimodipine-Induced Blood Pressure Changes Can Predict Delayed Cerebral Ischemia

Corinne Fischer et al. Front Neurol. .

Abstract

Background: Early diagnosis of delayed cerebral ischemia (DCI) in patients after aneurysmal subarachnoid hemorrhage (aSAH) still poses a leading problem in neurointensive care. The aim of this study was to analyze the effect of oral Nimodipine administration on systemic blood pressure in patients with evolving DCI compared to patients without DCI. Methods: Systolic (SBP), mean (MAP), and diastolic (DBP) blood pressures were analyzed at the time of Nimodipine administration and additionally 30, 60, and 120 min thereafter on days 1, 3, and 5 after aSAH. Additionally, the 24 h period preceding DCI and in patients without DCI day 10 after aSAH were analyzed. Statistical analysis was performed for SBP, MAP and DBP at time of Nimodipine administration and for the maximal drop in blood pressure after Nimodipine administration. Results: Thirty patients with aSAH were retrospectively analyzed with 17 patients developing DCI ("DCI") and 13 patients who did not ("Non-DCI"). DCI patients showed a more pronounced rise in MAP and DBP over the examined time period as well as a higher decrease in SBP following Nimodipine administration. A fall of 18 mmHg in SBP after Nimodipine administration showed a sensitivity of 82.4% and specificity of 92.3% for occurrence of DCI. Conclusion: An increase of MAP and DBP after aSAH and a heightened sensitivity to Nimodipine administrations may serve as additional biomarkers for early detection of evolving DCI.

Keywords: Nimodipine; blood pressure variability; cerebral infarction; cerebral perfusion; cerebral vasospasm; delayed cerebral ischemia; hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bar graphs showing systemic blood pressure at t0 and maximal blood pressure changes after Nimodipine administration in patients with evolving delayed cerebral ischemia (DCI, white) and patients without DCI (Non-DCI, gray). (A) Systolic (SBP), (B) mean arterial (MAP), and (C) diastolic (DBP) blood pressures at time of Nimodipine administration (t0). (D) SBP, (E) MAP, and (F) DBP changes after Nimodipine administration. Event = day preceding DCI or day 10 in patients without DCI. Mean ± Standard error of the mean.

Similar articles

Cited by

References

    1. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. (2007) 369:306–18. 10.1016/S0140-6736(07)60153-6 - DOI - PubMed
    1. Adamczyk P, He S, Amar AP, Mack WJ. Medical management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a review of current and emerging therapeutic interventions. Neurol Res Int. (2013) 2013:1–10. 10.1155/2013/462491 - DOI - PMC - PubMed
    1. Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, Manno EM, et al. . Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke. (2004) 35:1862–6. 10.1161/01.STR.0000133132.76983.8e - DOI - PubMed
    1. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. . Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J Neurosurg. (2005) 103:9–17. 10.3171/jns.2005.103.1.0009 - DOI - PubMed
    1. Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke. (2007) 38:1831–6. 10.1161/STROKEAHA.106.477976 - DOI - PubMed